Jounce Therapeutics Inc (JNCE) Stock
JNCE is no longer traded. Jounce Therapeutics was delisted from the Nasdaq in May 2023.
Prices on this page are historical; the last trade was May 3, 2023 at $1.88.
Jounce Therapeutics stock price history
JNCE final trading statistics
- Final close
- $1.88
- Final trading day
- May 3, 2023
- Market cap at delisting
- $98.95M
- Shares outstanding
- 52.64M
- Final 52-week range
- $0.58 – $5.87
- Avg. volume (final 3 mo.)
- 3,138,333
- All-time high (split-adj.)
- $28.46 · May 2017
- All-time low (split-adj.)
- $0.64 · Dec 2022
- Return since IPO
- -88.2%
- Beta
- 0.75
- Book value / share
- $3.54
- Price / book
- 0.53
Jounce Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $82.00M | -$50.9M | -$0.99 |
| FY2021 | $26.88M | -$90.9M | -$1.84 |
| FY2020 | $62.34M | -$43.8M | -$1.47 |
| FY2019 | $147.87M | $56.8M | $1.63 |
| FY2018 | $65.20M | -$27.4M | -$0.83 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Jounce Therapeutics Inc
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy. In addition, its preclinical products are JTX-1484, a monoclonal antibody designed to reduce myeloid-mediated immune suppression; and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression and activate T and NK cells. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Jounce Therapeutics stock FAQ
What happened to Jounce Therapeutics stock?
Jounce Therapeutics stock was delisted from the Nasdaq. Its final close was $1.88 on May 3, 2023.
Is JNCE stock still trading?
No. JNCE was delisted from the Nasdaq in May 2023 and no longer trades on a U.S. exchange.
What was the last price of JNCE stock?
JNCE closed at $1.88 on its final trading day, May 3, 2023, for a market value of about $98.95M.
What were Jounce Therapeutics's revenue and earnings in its last full fiscal year?
Jounce Therapeutics reported revenue of $82.00M and net income of -$50.9M in fiscal 2022, its last full year as a public company.
When did Jounce Therapeutics go public?
Jounce Therapeutics Inc stock began trading on January 27, 2017.